West China Biomedical Big Data Center, West China Hospital, Sichuan University, Guo Xue Lane 37#, Chengdu, 610041, China.
Med-X Center for Informatics, Sichuan University, Chengdu, China.
BMC Med. 2021 Nov 16;19(1):301. doi: 10.1186/s12916-021-02177-0.
With the increasing number of people infected with and recovered from coronavirus disease 2019 (COVID-19), the extent of major health consequences of COVID-19 is unclear, including risks of severe secondary infections.
Based on 445,845 UK Biobank participants registered in England, we conducted a matched cohort study where 5151 individuals with a positive test result or hospitalized with a diagnosis of COVID-19 were included in the exposed group. We then randomly selected up to 10 matched individuals without COVID-19 diagnosis for each exposed individual (n = 51,402). The life-threatening secondary infections were defined as diagnoses of severe secondary infections with high mortality rates (i.e., sepsis, endocarditis, and central nervous system infections) from the UK Biobank inpatient hospital data, or deaths from these infections from mortality data. The follow-up period was limited to 3 months after the initial COVID-19 diagnosis. Using a similar study design, we additionally constructed a matched cohort where exposed individuals were diagnosed with seasonal influenza from either inpatient hospital or primary care data between 2010 and 2019 (6169 exposed and 61,555 unexposed individuals). After controlling for multiple confounders, Cox models were used to estimate hazard ratios (HRs) of life-threatening secondary infections after COVID-19 or seasonal influenza.
In the matched cohort for COVID-19, 50.22% of participants were male, and the median age at the index date was 66 years. During a median follow-up of 12.71 weeks, the incidence rate of life-threatening secondary infections was 2.23 (123/55.15) and 0.25 (151/600.55) per 1000 person-weeks for all patients with COVID-19 and their matched individuals, respectively, which corresponded to a fully adjusted HR of 8.19 (95% confidence interval [CI] 6.33-10.59). The corresponding HR of life-threatening secondary infections among all patients with seasonal influenza diagnosis was 4.50, 95% CI 3.34-6.08 (p for difference < 0.01). Also, elevated HRs were observed among hospitalized individuals for life-threatening secondary infections following hospital discharge, both in the COVID-19 (HR = 6.28 [95% CI 4.05-9.75]) and seasonal influenza (6.01 [95% CI 3.53-10.26], p for difference = 0.902) cohorts.
COVID-19 patients have increased subsequent risks of life-threatening secondary infections, to an equal extent or beyond risk elevations observed for patients with seasonal influenza.
随着感染和康复 2019 年冠状病毒病(COVID-19)的人数不断增加,COVID-19 对主要健康后果的严重程度尚不清楚,包括严重继发感染的风险。
基于英格兰的 445845 名英国生物库参与者,我们进行了一项匹配队列研究,其中包括 5151 名检测结果呈阳性或因 COVID-19 住院的个体作为暴露组。然后,我们为每个暴露个体随机选择最多 10 名未诊断 COVID-19 的匹配个体(n=51402)。危及生命的继发感染定义为从英国生物库住院患者数据中诊断出严重继发感染且死亡率高(即败血症、心内膜炎和中枢神经系统感染),或从死亡率数据中死于这些感染的情况。随访期限制在最初 COVID-19 诊断后的 3 个月内。使用类似的研究设计,我们还构建了一个匹配队列,其中暴露个体在 2010 年至 2019 年期间因季节性流感从住院或初级保健数据中被诊断出(暴露个体 6169 人,未暴露个体 61555 人)。在控制了多个混杂因素后,使用 Cox 模型估计 COVID-19 或季节性流感后危及生命的继发感染的风险比(HR)。
在 COVID-19 的匹配队列中,50.22%的参与者为男性,指数日期的中位年龄为 66 岁。在中位随访 12.71 周期间,所有 COVID-19 患者及其匹配个体的危及生命的继发感染发生率分别为每 1000 人-周 2.23(123/55.15)和 0.25(151/600.55),这对应于完全调整后的 HR 为 8.19(95%置信区间[CI]6.33-10.59)。所有季节性流感诊断患者的危及生命的继发感染的相应 HR 为 4.50,95%CI 3.34-6.08(p<0.01)。此外,在 COVID-19(HR=6.28[95%CI 4.05-9.75])和季节性流感(6.01[95%CI 3.53-10.26])队列中,出院后住院患者发生危及生命的继发感染的 HR 也较高,差异无统计学意义(p=0.902)。
COVID-19 患者随后发生危及生命的继发感染的风险增加,其程度与季节性流感患者的风险增加程度相当或更高。